Successful management of hepatitis B and C coinfection: a case report

Jeffrey Freidenson-Bejar; Alvaro Bellido-Caparo; Martin Tagle

doi:10.47892/rgp.2024.443.1732

Autores/as

Jeffrey Freidenson-Bejar Universidad Peruana Cayetano Heredia, Lima, Peru. https://orcid.org/0009-0004-4751-1921
Alvaro Bellido-Caparo Universidad Peruana Cayetano Heredia, Lima, Peru; Hospital Cayetano Heredia, Lima, Peru. https://orcid.org/0000-0002-7710-0662
Martin Tagle Universidad Peruana Cayetano Heredia, Lima, Peru. https://orcid.org/0000-0001-8717-6196

DOI:

https://doi.org/10.47892/rgp.2024.443.1732

Palabras clave:

Hepatitis B, Hepatitis C, Coinfection, Antiviral agents

Resumen

We report the case of a patient with chronic hepatitis B and C managed with direct-acting antivirals in an outpatient setting. Chronic hepatitis B was first treated with entecavir before initiating treatment for chronic hepatitis C. The patient achieved viral suppression for hepatitis B and sustained virological response for hepatitis C. As direct-acting antivirals become more available, healthcare practitioners should be familiar with managing patients with chronic coinfection.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Citas

Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res. 2019;19(1):765. doi: 10.1186/s12913-019-4635-7.

Shih Y-F, Liu C-J. Hepatitis C virus and hepatitis B virus coinfection. Viruses. 2020;12(7):741. doi: 10.3390/v12070741.

Wu J-C, Chen C-L, Hou M-C, Chen T-Z, Lee S-D, Lo K-J. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: Application and limitations of the polymerase chain reaction. Hepatology. 1994;19(4):836-40. doi: 10.1002/hep.1840190406.

Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58(2):538-45. doi: 10.1002/hep.26400.

Vaccination coverage among adults in the United States, National Health Interview Survey, 2021 [Internet]. Atlanta: Centers for Disease Control and Prevention; 2023 [cited 2024 May 18]. Available from: https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccinationcoverage-adults-2021.html

Mavilia MG, Wu GY. HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol. 2018;6(3):296-305. doi: 10.14218/JCTH.2018.00016.

Ma AT, Feld JJ. Hepatitis B reactivation with hepatitis C treatment: Bringing some clarity to the black box. Gastroenterology. 2018;154(4):795-8. doi: 10.1053/j.gastro.2018.02.005.

Terrault NA, Lok ASF, McMahon BJ, Chang K, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99. doi: 10.1002/hep.29800.

American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C [Internet]. AASLD-IDSA; 2014 [cited 2024 May 18]. Available from: http://www.hcvguidelines.org

Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132-136. doi: 10.1016/j.cgh.2016.06.023.

Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol. 2018;24(28):3181-3191. doi: 10.3748/wjg.v24.i28.3181.

Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683-694. doi: 10.1093/cid/civ948.

Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther. 2007;26 Suppl 1:13-9. doi: 10.1111/j.1365-2036.2007.03512.x.

Soliman Z, El Kassas M, Elsharkawy A, Elbadry M, Hamada Y, ElHusseiny R, et al. Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. Platelets. 2020;32(3):383-90. doi: 10.1080/09537104.2020.1742313.

Rockey DC, Friedman SL. Fibrosis regression after eradication of hepatitis C virus: From bench to bedside. Gastroenterology. 2021;160(5):1502-1520.e1. doi: 10.1053/j.gastro.2020.09.065.

Cedrón-Cheng H, Siccha Sinti C, Tagle Arróspide M. Mejora del curso clínico de la cirrosis hepática por virus de hepatitis C posterior al tratamiento efectivo con antivirales de acción directa. Rev Gastroenterol Peru. 2021;41(4):257-60. doi: 10.47892/rgp.2021.414.1350.